Myasthenia Gravis - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myasthenia Gravis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H2 2016', provides an overview of the Myasthenia Gravis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
- The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects
- The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Myasthenia Gravis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Myasthenia Gravis Overview 9
Therapeutics Development 10
Pipeline Products for Myasthenia Gravis - Overview 10
Pipeline Products for Myasthenia Gravis - Comparative Analysis 11
Myasthenia Gravis - Therapeutics under Development by Companies 12
Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 14
Myasthenia Gravis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Myasthenia Gravis - Products under Development by Companies 18
Myasthenia Gravis - Products under Investigation by Universities/Institutes 19
Myasthenia Gravis - Companies Involved in Therapeutics Development 20
Achillion Pharmaceuticals, Inc. 20
Alexion Pharmaceuticals, Inc. 21
Alpha Cancer Technologies Inc. 22
arGEN-X BV 23
Biokine Therapeutics Ltd. 24
BioMarin Pharmaceutical Inc. 25
CuraVac, Inc. 26
GlaxoSmithKline Plc 27
Grifols, S.A. 28
HanAll Biopharma Co., Ltd. 29
Karus Therapeutics Limited 30
Millennium Pharmaceuticals Inc 31
Neurotune AG 32
Novartis AG 33
Pfizer Inc. 34
ReceptoPharm, Inc. 35
Regenesance BV 36
Shire Plc 37
Toleranzia AB 38
Myasthenia Gravis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ACT-101 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
amifampridine phosphate - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ARGX-113 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BB-008 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
belimumab - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
BKT-130 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
bortezomib - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
CFZ-533 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
CVMG-01 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
eculizumab - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
GL-2045 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
HL-161 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
immune globulin (human) - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
KA-1463 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
methotrexate - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
NT-1654 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Recombinant Protein for Myasthenia Gravis - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
regenemab - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
RPI-78M - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
SM-201 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Vaccine for Myasthenia Gravis - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Vaccine for Myasthenia Gravis - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Myasthenia Gravis - Dormant Projects 101
Myasthenia Gravis - Discontinued Products 102
Myasthenia Gravis - Product Development Milestones 103
Featured News & Press Releases 103
Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 103
Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 105
Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis 107
Jan 26, 2016: Toleranzia takes an important step towards patent granting in Europe 107
Dec 09, 2015: Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis 107
May 29, 2015: Double recognition of Toleranzia 108
Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis 109
Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis 109
Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 110
Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 111
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 111
Apr 24, 2014: Toleranzia supported by VINNOVA 112
Apr 24, 2013: arGEN-X Advances ARGX-113 Into Preclinical Development For Autoimmune Disorders 113
Sep 14, 2011: Phase II Study of Eculizumab In Patients With Severe And Refractory Generalized Myasthenia Gravis Presented At MGFA Annual Meeting 113
Aug 06, 2009: European Commission And U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation For The Treatment Of Atypical Hemolytic Uremic Syndrome (aHUS) 114
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development for Myasthenia Gravis, H2 2016 10
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 20
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2016 21
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc., H2 2016 22
Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2016 23
Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H2 2016 24
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc., H2 2016 25
Myasthenia Gravis - Pipeline by CuraVac, Inc., H2 2016 26
Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2016 27
Myasthenia Gravis - Pipeline by Grifols, S.A., H2 2016 28
Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 29
Myasthenia Gravis - Pipeline by Karus Therapeutics Limited, H2 2016 30
Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 31
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2016 32
Myasthenia Gravis - Pipeline by Novartis AG, H2 2016 33
Myasthenia Gravis - Pipeline by Pfizer Inc., H2 2016 34
Myasthenia Gravis - Pipeline by ReceptoPharm, Inc., H2 2016 35
Myasthenia Gravis - Pipeline by Regenesance BV, H2 2016 36
Myasthenia Gravis - Pipeline by Shire Plc, H2 2016 37
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Stage and Target, H2 2016 41
Number of Products by Stage and Mechanism of Action, H2 2016 43
Number of Products by Stage and Route of Administration, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 47
Myasthenia Gravis - Dormant Projects, H2 2016 101
Myasthenia Gravis - Discontinued Products, H2 2016 102